Becton, Dickinson Says Revello Delivers High Patency in Iliac Artery Disease
MT newswire2026/10/07 13:1409:14 AM EDT, 10/07/2026 (MT Newswires) -- Becton, Dickinson (BDX) said Wednesday that nine-month follow-up data from an ongoing study evaluating the Revello Vascular Covered Stent in patients with iliac artery disease met its primary composite safety and effectiveness endpoint. The company said that treatment with the stent showed 97.2% primary patency, 98.3% freedom from clinically driven target lesion revascularization, and no device- or procedure-related deaths. Failure rate was 2.8%, below the 19% prespecified performance goal, the company said. The company added that patients exhibited "meaningful gains" in daily function and mobility.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SNT Holdings, Related Party Raise Combined Stake in SNTEnergy to 55.75% From 52.75%
Cold wave and rising fuel costs drive electricity prices in northeastern Japan and Tokyo to a four-year high
Japan's spot electricity prices surged to multi-year highs over the weekend.
Google (GOOGL.US) warns that new Australian cybersecurity regulations may cut off minors' access to Gmail
Google stated that a new cybersecurity bill in Australia could prevent minors from using Gmail.
Canaccord Genuity: Lowers Oklo's target price to $66
Crypto prices
More
